Global Low-Density Lipoprotein Test Market Size and Forecast 2024-2033|Abbott Laboratories, Qiagen N.V., Randox Laboratories Ltd., Eurofins Scientific SE, Danaher Corporation

The Low-Density Lipoprotein Test by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Low-Density Lipoprotein Test Market:

https://www.thebusinessresearchcompany.com/report/low-density-lipoprotein-test-global-market-report

According to The Business Research Company’s Low-Density Lipoprotein Test, The low-density lipoprotein test market size has grown steadily in recent years. It will grow from $8.11 billion in 2023 to $8.46 billion in 2024 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to research advancements in cardiovascular medicine, increased awareness of heart health, shift in treatment paradigms, clinical guidelines and recommendations, focus on preventive healthcare.

The low-density lipoprotein test market size is expected to see steady growth in the next few years. It will grow to $10.24 billion in 2028 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to increasing healthcare expenditure, aging population demographics, rise in cardiovascular disease burden, shift towards personalized medicine, healthcare policy and guidelines.. Major trends in the forecast period include rising cardiovascular disease prevalence, emphasis on preventive healthcare, personalized medicine and treatment, focus on health awareness and education, regulatory guidelines and recommendations.

The rise in the prevalence of cardiovascular diseases is expected to propel the growth of the low-density lipoprotein test market going forward. Cardiovascular diseases refer to a type of condition that affects the heart or blood vessels. The LDL test is used to treat cardiovascular diseases by directly measuring low-density lipoprotein levels in the heart. For instance, in October 2022, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, heart disease is the top cause of mortality in the United States for both genders and members of most racial and ethnic groups. Heart disease claimed almost 695,000 people in the United States in 2021, accounting for one in every five deaths. In 2020, the most common type of heart disease, coronary heart disease, killed 375,476 people. Therefore, the rise in the prevalence of cardiovascular diseases is driving the growth of the low-density lipoprotein test market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=9395&type=smp

The low-density lipoprotein test market covered in this report is segmented –

1) By Product Type: LDL-C, LDL-P, LDL-B, Other Products

2) By Component: Kits, Reagents, Devices, Other Components

3) By Disease Type: Diabetes, Stroke, Atherosclerosis, Obesity, Dyslipidaemia, Carotid Artery Disease, Peripheral Arterial Disease, Angina, Other Disease Types

4) By Distribution Channel: Direct Tenders, Retail

5) By End User: Hospitals, Clinics, Ambulatory Care, Research Laboratory, Other End Users

Product innovations are a key trend gaining popularity in the low-density lipoprotein test markets. Major companies operating in the low-density lipoprotein test market are introducing innovative products to sustain their position in the market. For instance, in December 2021, Novartis AG, a Switzerland-based multinational pharmaceutical corporation, launched Leqvio (Inclisiran), a first-in-class siRNA (small interfering RNA therapy) to lower low-density lipoprotein cholesterol. This medication provides effective and sustained reductions in low-density lipoprotein cholesterol. Leqvio is the first and only small interfering RNA (siRNA) medication for lowering LDL-C (bad cholesterol) that has received FDA approval, requiring just two maintenance doses per year. For some patients with atherosclerotic cardiovascular disease (ASCVD) receiving maximally tolerated statin therapy, Leqvio offers an effective and long-lasting LDL-C decrease of up to 52% in comparison to placebo. Leqvio is a ground-breaking method to reduce LDL-C that also opens new opportunities for how healthcare systems can affect cardiovascular disease.

The low-density lipoprotein test market report table of contents includes:

1. Executive Summary

2. Low-Density Lipoprotein Test Market Characteristics

3. Low-Density Lipoprotein Test Market Trends And Strategies

4. Low-Density Lipoprotein Test Market – Macro Economic Scenario

5. Global Low-Density Lipoprotein Test Market Size and Growth

26. South America Low-Density Lipoprotein Test Market

27. Brazil Low-Density Lipoprotein Test Market

28. Middle East Low-Density Lipoprotein Test Market

29. Africa Low-Density Lipoprotein Test Market

30. Low-Density Lipoprotein Test Market Competitive Landscape And Company Profiles

Top Major Players: